Melanotan II is the original 1990s tanning and libido research compound, developed at the University of Arizona, and the direct parent molecule of two drugs that are actually FDA-approved: afamelanotide (Melanotan 1, Scenesse) and bremelanotide (PT-141, Vyleesi), each created by modifying MT-II specifically to remove one of its side effects. MT-II itself has never been approved anywhere and has never completed a registered human trial for tanning, libido or appetite. It circulates as an unregulated injectable, and its documented harms, priapism and darkening of existing moles, come from individual case reports, not trials.
Ask about Melanotan I and II
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Synthetic cyclic alpha-MSH analogue, non-selective melanocortin receptor agonist |
| Primary research interest | Skin tanning/photoprotection, libido, appetite (parent compound of two approved drugs) |
| Highest available evidence | Tier 2: case reports of harms only; no completed human trial for tanning, libido, or appetite |
| Human research available | No trial for its circulated uses; one Phase 2 trial (vitiligo, unrelated indication) was recruiting |
| Development status | Never advanced to approval; parent molecule of afamelanotide (Scenesse) and bremelanotide (Vyleesi), each derived by modification to remove a side effect |
| Regulatory status | Not approved anywhere for any use; sold as an unregulated research chemical |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Melanotan II |
| Alternative names | MT-2, MT2, “Barbie drug” |
| Molecular formula | C50H69N15O9 |
| Molecular weight | ≈1024.2 g/mol |
| CAS Registry Number | 121062-08-6 |
| PubChem CID | 92432 |
| Peptide class | Cyclic alpha-MSH analogue, non-selective melanocortin receptor (MC1R/MC4R) agonist |
| Primary biological target | Melanocortin receptors (non-selective) |
| Developer / originator | University of Arizona, 1990s |
| Development status | Never approved; parent molecule of afamelanotide and bremelanotide, each derived to remove one of MT-II’s side effects |
What it is
Melanotan II (MT-II) is a synthetic cyclic alpha-MSH analogue and non-selective melanocortin receptor agonist, originally developed at the University of Arizona in the 1990s as a tanning and libido research compound. It is the parent molecule both Melanotan 1 (afamelanotide, FDA-approved as Scenesse) and PT-141 (bremelanotide, FDA-approved as Vyleesi) were derived from, each by a chemical modification made specifically to reduce a side effect associated with MT-II itself.
MT-II has never been approved for any use, in any country, and has never completed a registered human clinical trial for tanning, libido, appetite or any other indication. One Phase 2 trial (NCT07437560) was recruiting as of this entry, testing MT-II as an adjunct to phototherapy for vitiligo, a use unrelated to why it circulates.
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use | Route | Amount reported | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|
| Tanning / libido, human research | Not reported | Not established | Not reported | Not reported | No completed human trial of MT-II itself for tanning, libido, or appetite |
| Tanning / libido, general use | Subcutaneous injection | 0.25 to 1 mg per dose | Every 1 to 3 days during a loading phase, then less often | Ongoing, cyclical | Community / vendor reported: no completed trial exists to check this figure against |
Potential benefits and research applications
Skin tanning and photoprotection, the original rationale, never completed in a human trial
MT-II was originally developed to stimulate melanin production for tanning and skin photoprotection. This research led directly to afamelanotide’s approval for erythropoietic protoporphyria, but MT-II itself has never completed a registered human trial for tanning as an indication.
Evidence: has been reported anecdotally (Tier 6, community-reported information); has not been established by any completed human trial of MT-II itself.
Libido and sexual function, the effect that led to bremelanotide’s development
MT-II produces pronounced, often prolonged erections as a non-selective melanocortin-receptor side effect, which is what drove interest in it as a libido compound and what PT-141 (bremelanotide) was specifically engineered to reduce while keeping a milder desire-enhancing effect.
Evidence: has been reported anecdotally and in case reports describing this effect as a complication (Tier 6/2); has not been established as a safe or effective use, and no completed trial tested MT-II for this purpose.
Appetite suppression, a proposed melanocortin-pathway effect with no dedicated human trial
The melanocortin system MT-II activates is also involved in appetite regulation, and appetite suppression is sometimes cited as a secondary reason for its use. No dedicated human trial of MT-II for this purpose was located for this entry.
Evidence: unverified; no established or reliably sourced human trial data was identified for this specific use.
The documented harms
Because MT-II circulates as an unregulated injectable, its adverse effects are documented mainly through case reports rather than trials. A published case report describes acute low-flow priapism after subcutaneous MT-II injection, managed with cavernosal aspiration and phenylephrine, with erectile function not yet recovered at four-week follow-up; the authors describe this as a previously unreported complication.
A separate case report describes a 16-year-old with a family history of atypical mole and melanoma syndrome (FAMMM) who developed darkening of multiple melanocytic nevi and an enlarging nevus after self-injecting Melanotan II and using UV tanning beds, prompting concern for malignant change. MT-II’s mechanism is direct stimulation of melanocyte activity; darkening or changing of existing moles is a mechanistically expected risk, not a coincidental one, and is the reason dermatology bodies have specifically warned against its use.
Nausea, flushing, and spontaneous erections are common and expected at typical doses, consistent with non-selective melanocortin receptor activation; MT-II’s persistent erection effect, more pronounced and longer-lasting than PT-141’s, is exactly what PT-141 was chemically modified to reduce.
What is not known
Any dose, purity or safety standard for MT-II as sold, since it has never been manufactured or studied as a regulated pharmaceutical product.
Long-term melanoma risk from repeated melanocyte stimulation. No long-term surveillance study of MT-II users was located; the concerning findings that exist are individual case reports.
Frequently asked questions
What is Melanotan II?
Melanotan II is a synthetic alpha-MSH analogue developed in the 1990s as a tanning and libido research compound. It is the unmodified parent molecule of two FDA-approved drugs, afamelanotide and bremelanotide.
How does Melanotan II work?
It is a non-selective melanocortin receptor agonist, stimulating melanin production and activating pathways involved in sexual desire and appetite, without the receptor selectivity engineered into the two drugs later derived from it.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified. MT-II has never completed a registered human trial for tanning, libido or appetite.
What dosage commonly circulates online?
Circulating dosing describes 0.25 to 1 milligram by subcutaneous injection, several times weekly. This figure has no completed human trial behind it; the two drugs derived from MT-II have their own separate, approved doses that do not apply to MT-II itself.
Has Melanotan II been studied in humans?
It has never completed a registered clinical trial for tanning, libido or appetite. One Phase 2 trial testing it as an adjunct to phototherapy for vitiligo was recruiting as of this entry’s last check, an unrelated indication.
Is Melanotan II approved for use?
No. It has never been approved for any use in any country and is sold as an unregulated research chemical.
What routes of administration are reported?
Subcutaneous injection is essentially the only reported route.
Is Melanotan II the same as PT-141 or Melanotan 1?
No. Both were derived from MT-II by specific chemical modifications made to remove one of its side effects, and both are approved drugs with their own separate trial data. MT-II itself remains unapproved and untested in a completed human trial.
What side effects have been reported?
Nausea, flushing and spontaneous, often prolonged erections are common and expected. Case reports document acute priapism requiring medical intervention and darkening or changing of existing moles, a mechanistically expected risk given MT-II’s direct stimulation of melanocyte activity.
What remains unknown about Melanotan II?
Any dose, purity or safety standard, since it has never been manufactured or studied as a regulated pharmaceutical, and long-term melanoma risk from repeated melanocyte stimulation, for which no surveillance study exists.
Bottom line
Melanotan II is the unmodified ancestor of two real, FDA-approved drugs, but it was never approved itself and has never completed a human clinical trial for the uses it is actually sold for. What exists instead is a body of individual case reports documenting real harms, priapism requiring medical intervention and concerning changes to existing moles, that are the specific reason the two derivative drugs were chemically engineered to remove MT-II’s more extreme effects in the first place.
Sources
- Dreyer BA, et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep 2019;12(2). Human case report, acute low-flow priapism after subcutaneous Melanotan injection. PMID 30796078
- Sivyer GW. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatol Pract Concept 2012;2(3):203a10. Human case report, mole darkening after self-injected Melanotan II. PMID 23785612
- Hudson Biotech. Phase 2 randomized, double-blind, placebo-controlled study of Melanotan II as an adjunct to narrowband UV-B phototherapy in nonsegmental vitiligo. Recruiting. NCT07437560
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
| Trial | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|
| Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo NCT07437560 | Phase 2 | Recruiting | Hudson Biotech | 60 | Feb 14, 2027 | Nov 12, 2026 |
Compare Melanotan 2 with related compounds
Research area: Sexual health and melanocortin.